Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings data on Tuesday, May, 9th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. The firm had revenue of $110.30 million for the quarter, compared to analyst estimates of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The business's quarterly revenue was up 199.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.52) earnings per share. View Ionis Pharmaceuticals' Earnings History.

14 brokerages have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $17.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $44.00 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (7/12/2017)
• 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
• 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
• 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)

Some companies that are related to Ionis Pharmaceuticals include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), United Therapeutics Corporation (UTHR), ICON PLC (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), Puma Biotechnology (PBYI), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and INC Research Holdings (INCR).

Ionis Pharmaceuticals' management team includes the folowing people:

• Stanley T. Crooke M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
• Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
• B. Lynne Parshall Esq., Chief Operating Officer, Corporate Secretary, Director
• Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
• C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
• Richard S. Geary Ph.D., Senior Vice President - Development
• Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
• Sarah Boyce, Chief Business Officer
• Spencer R. Berthelsen M.D., Independent Director
• Breaux B. Castleman, Independent Director

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Creative Planning (0.02%), Sit Investment Associates Inc. (0.02%), Aperio Group LLC (0.01%), US Bancorp DE (0.00%), Bank of Montreal Can (0.00%) and Capstone Asset Management Co. (0.00%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Sit Investment Associates Inc., Creative Planning and Capstone Asset Management Co.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Ionis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Aperio Group LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $54.42.